A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1992-08

AUTHORS

A R Dixon, L Jackson, S Chan, J Haybittle, R W Blamey

ABSTRACT

Sixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to receive four course of mitozantrone, 14 mg m-2 (n = 30) intravenously every 3 weeks (9 weeks total) or megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disease control for a minimum period of 6 months i.e., lack of progression; seven patients (23%) showed objective response to mitozantrone compared to four (13%) receiving megesterol. Non-progressive disease occurred in all sites, including visceral metastases and receptor negative patients. There were no significant differences between treatment groups in the median time (5 months each) to disease progression response duration or survival (13 months megesterol, 11 months mitozantrone) from commencing second-line therapy. Toxicity was considerably higher in the mitozantrone group. Second-line hormonal therapies can produce similar therapeutic results as those achieved from a short course of a 'short option' single agent cytotoxic in patients who were previously thought hormone insensitive. Provided that the patient does not have life threatening disease a trial of megesterol acetate is worth consideration in that it does not prejudice subsequent response to combination cytotoxic chemotherapy. More... »

PAGES

bjc1992277

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1992.277

DOI

http://dx.doi.org/10.1038/bjc.1992.277

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031193368

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1503915


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Megestrol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Megestrol Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitoxantrone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Probability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "City Hospital, Nottingham, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dixon", 
        "givenName": "A R", 
        "id": "sg:person.01127263010.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127263010.17"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Jackson", 
        "givenName": "L", 
        "id": "sg:person.01362576661.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362576661.68"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Chan", 
        "givenName": "S", 
        "id": "sg:person.010333513372.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010333513372.78"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Haybittle", 
        "givenName": "J", 
        "id": "sg:person.063512001.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.063512001.95"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Blamey", 
        "givenName": "R W", 
        "id": "sg:person.015650304144.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015650304144.58"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00174161", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000315787", 
          "https://doi.org/10.1007/bf00174161"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198910000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003943693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198910000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003943693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198910000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003943693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1445-2197.1984.tb06679.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004642141"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(89)90259-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007284388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19820201)49:3<413::aid-cncr2820490303>3.0.co;2-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008868897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011360956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0010-468x(72)90019-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017943682"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0010-468x(72)90019-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017943682"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(86)90012-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026924483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bjs.1800730925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027544360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(90)90277-c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045705046"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(90)90277-c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045705046"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(80)91066-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051618347"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079527123", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1992-08", 
    "datePublishedReg": "1992-08-01", 
    "description": "Sixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to receive four course of mitozantrone, 14 mg m-2 (n = 30) intravenously every 3 weeks (9 weeks total) or megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disease control for a minimum period of 6 months i.e., lack of progression; seven patients (23%) showed objective response to mitozantrone compared to four (13%) receiving megesterol. Non-progressive disease occurred in all sites, including visceral metastases and receptor negative patients. There were no significant differences between treatment groups in the median time (5 months each) to disease progression response duration or survival (13 months megesterol, 11 months mitozantrone) from commencing second-line therapy. Toxicity was considerably higher in the mitozantrone group. Second-line hormonal therapies can produce similar therapeutic results as those achieved from a short course of a 'short option' single agent cytotoxic in patients who were previously thought hormone insensitive. Provided that the patient does not have life threatening disease a trial of megesterol acetate is worth consideration in that it does not prejudice subsequent response to combination cytotoxic chemotherapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.1992.277", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "66"
      }
    ], 
    "name": "A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer", 
    "pagination": "bjc1992277", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "949a4cb19ef51988f7ace6dd79494a64cf302393c12ca53303a35bc6d2c5e60b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1503915"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1992.277"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031193368"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1992.277", 
      "https://app.dimensions.ai/details/publication/pub.1031193368"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000361_0000000361/records_54011_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.nature.com/articles/bjc1992277"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.277'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.277'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.277'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.277'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      21 PREDICATES      55 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1992.277 schema:about N0e360e6f7b834529bed195a0d498998b
2 N0fed5e6edaf1442fbb2a0fab9a096be9
3 N355abf50ef8d4e709731dfecc8d19538
4 N36b1a2a5e046457ea9ff4582c889d6e8
5 N3afa29e45cdd4dfba9a55f58e59b97c7
6 N58e2bdcad84f463a83bd111ab408a25d
7 N8454964796224ddf99a4196ce58bb3db
8 N84b42766b69a4bbb8bca30b74a5402bb
9 N8cd7ba3760de46689075183dc3f8f009
10 N912e0ad59eff4ff2a7d055e78408ee68
11 Naf0f86d6e9bd414cbfee359da6161f3c
12 Nc075661ac21f42149d156ac0fb3c70b3
13 Ncfe601b39af74ed9be1aaca14f7b26d9
14 Nf5506018dae34344b21c6acc88f5d32b
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author Nf321985a813041c9abc9ae7f54493b36
18 schema:citation sg:pub.10.1007/bf00174161
19 https://app.dimensions.ai/details/publication/pub.1079527123
20 https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f
21 https://doi.org/10.1002/1097-0142(19820201)49:3<413::aid-cncr2820490303>3.0.co;2-s
22 https://doi.org/10.1002/bjs.1800730925
23 https://doi.org/10.1016/0010-468x(72)90019-0
24 https://doi.org/10.1016/0140-6736(90)90277-c
25 https://doi.org/10.1016/0277-5379(86)90012-x
26 https://doi.org/10.1016/0277-5379(89)90259-9
27 https://doi.org/10.1016/s0140-6736(80)91066-1
28 https://doi.org/10.1097/00000421-198910000-00006
29 https://doi.org/10.1111/j.1445-2197.1984.tb06679.x
30 schema:datePublished 1992-08
31 schema:datePublishedReg 1992-08-01
32 schema:description Sixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to receive four course of mitozantrone, 14 mg m-2 (n = 30) intravenously every 3 weeks (9 weeks total) or megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disease control for a minimum period of 6 months i.e., lack of progression; seven patients (23%) showed objective response to mitozantrone compared to four (13%) receiving megesterol. Non-progressive disease occurred in all sites, including visceral metastases and receptor negative patients. There were no significant differences between treatment groups in the median time (5 months each) to disease progression response duration or survival (13 months megesterol, 11 months mitozantrone) from commencing second-line therapy. Toxicity was considerably higher in the mitozantrone group. Second-line hormonal therapies can produce similar therapeutic results as those achieved from a short course of a 'short option' single agent cytotoxic in patients who were previously thought hormone insensitive. Provided that the patient does not have life threatening disease a trial of megesterol acetate is worth consideration in that it does not prejudice subsequent response to combination cytotoxic chemotherapy.
33 schema:genre research_article
34 schema:inLanguage en
35 schema:isAccessibleForFree true
36 schema:isPartOf N6ddaf52656a04246a789d7b3819d144a
37 Nd43907a554be4e7a9d8486fa7dfeb3bf
38 sg:journal.1017082
39 schema:name A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer
40 schema:pagination bjc1992277
41 schema:productId N07d5c26196d44cc5b01bee9b71148518
42 N1b008ee4672548a2a015789adb52867b
43 N4243d1ba9a674eb5a30c5b87758c29e8
44 N892bb9a1581648a4bdea513783095a22
45 Nf5af91cf16f54697ae7619a67e95b348
46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031193368
47 https://doi.org/10.1038/bjc.1992.277
48 schema:sdDatePublished 2019-04-11T12:15
49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
50 schema:sdPublisher N65c4413db40a4ed2897d613dc08615d4
51 schema:url http://www.nature.com/articles/bjc1992277
52 sgo:license sg:explorer/license/
53 sgo:sdDataset articles
54 rdf:type schema:ScholarlyArticle
55 N048e4000e8744412bffa9663d28891eb rdf:first sg:person.010333513372.78
56 rdf:rest N304a8b3592334c18a7c59db65b5324ea
57 N06747265e488406c88a286069d1f1559 rdf:first sg:person.015650304144.58
58 rdf:rest rdf:nil
59 N07d5c26196d44cc5b01bee9b71148518 schema:name doi
60 schema:value 10.1038/bjc.1992.277
61 rdf:type schema:PropertyValue
62 N0e360e6f7b834529bed195a0d498998b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Receptors, Estrogen
64 rdf:type schema:DefinedTerm
65 N0fed5e6edaf1442fbb2a0fab9a096be9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Drug Resistance
67 rdf:type schema:DefinedTerm
68 N1b008ee4672548a2a015789adb52867b schema:name pubmed_id
69 schema:value 1503915
70 rdf:type schema:PropertyValue
71 N304a8b3592334c18a7c59db65b5324ea rdf:first sg:person.063512001.95
72 rdf:rest N06747265e488406c88a286069d1f1559
73 N355abf50ef8d4e709731dfecc8d19538 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Tamoxifen
75 rdf:type schema:DefinedTerm
76 N36b1a2a5e046457ea9ff4582c889d6e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Breast Neoplasms
78 rdf:type schema:DefinedTerm
79 N3afa29e45cdd4dfba9a55f58e59b97c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Female
81 rdf:type schema:DefinedTerm
82 N4243d1ba9a674eb5a30c5b87758c29e8 schema:name dimensions_id
83 schema:value pub.1031193368
84 rdf:type schema:PropertyValue
85 N4e3ebe2b572f4eeb80c132ca1d486d47 rdf:first sg:person.01362576661.68
86 rdf:rest N048e4000e8744412bffa9663d28891eb
87 N58e2bdcad84f463a83bd111ab408a25d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Neoplasm Staging
89 rdf:type schema:DefinedTerm
90 N65c4413db40a4ed2897d613dc08615d4 schema:name Springer Nature - SN SciGraph project
91 rdf:type schema:Organization
92 N6ddaf52656a04246a789d7b3819d144a schema:issueNumber 2
93 rdf:type schema:PublicationIssue
94 N8454964796224ddf99a4196ce58bb3db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Probability
96 rdf:type schema:DefinedTerm
97 N84b42766b69a4bbb8bca30b74a5402bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Megestrol Acetate
99 rdf:type schema:DefinedTerm
100 N892bb9a1581648a4bdea513783095a22 schema:name nlm_unique_id
101 schema:value 0370635
102 rdf:type schema:PropertyValue
103 N8cd7ba3760de46689075183dc3f8f009 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Mitoxantrone
105 rdf:type schema:DefinedTerm
106 N912e0ad59eff4ff2a7d055e78408ee68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Humans
108 rdf:type schema:DefinedTerm
109 Naf0f86d6e9bd414cbfee359da6161f3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Time Factors
111 rdf:type schema:DefinedTerm
112 Nc075661ac21f42149d156ac0fb3c70b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Prospective Studies
114 rdf:type schema:DefinedTerm
115 Ncfe601b39af74ed9be1aaca14f7b26d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Treatment Outcome
117 rdf:type schema:DefinedTerm
118 Nd43907a554be4e7a9d8486fa7dfeb3bf schema:volumeNumber 66
119 rdf:type schema:PublicationVolume
120 Nf321985a813041c9abc9ae7f54493b36 rdf:first sg:person.01127263010.17
121 rdf:rest N4e3ebe2b572f4eeb80c132ca1d486d47
122 Nf5506018dae34344b21c6acc88f5d32b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Megestrol
124 rdf:type schema:DefinedTerm
125 Nf5af91cf16f54697ae7619a67e95b348 schema:name readcube_id
126 schema:value 949a4cb19ef51988f7ace6dd79494a64cf302393c12ca53303a35bc6d2c5e60b
127 rdf:type schema:PropertyValue
128 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
129 schema:name Medical and Health Sciences
130 rdf:type schema:DefinedTerm
131 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
132 schema:name Oncology and Carcinogenesis
133 rdf:type schema:DefinedTerm
134 sg:journal.1017082 schema:issn 0007-0920
135 1532-1827
136 schema:name British Journal of Cancer
137 rdf:type schema:Periodical
138 sg:person.010333513372.78 schema:familyName Chan
139 schema:givenName S
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010333513372.78
141 rdf:type schema:Person
142 sg:person.01127263010.17 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
143 schema:familyName Dixon
144 schema:givenName A R
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127263010.17
146 rdf:type schema:Person
147 sg:person.01362576661.68 schema:familyName Jackson
148 schema:givenName L
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362576661.68
150 rdf:type schema:Person
151 sg:person.015650304144.58 schema:familyName Blamey
152 schema:givenName R W
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015650304144.58
154 rdf:type schema:Person
155 sg:person.063512001.95 schema:familyName Haybittle
156 schema:givenName J
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.063512001.95
158 rdf:type schema:Person
159 sg:pub.10.1007/bf00174161 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000315787
160 https://doi.org/10.1007/bf00174161
161 rdf:type schema:CreativeWork
162 https://app.dimensions.ai/details/publication/pub.1079527123 schema:CreativeWork
163 https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f schema:sameAs https://app.dimensions.ai/details/publication/pub.1011360956
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1002/1097-0142(19820201)49:3<413::aid-cncr2820490303>3.0.co;2-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1008868897
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1002/bjs.1800730925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027544360
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1016/0010-468x(72)90019-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017943682
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1016/0140-6736(90)90277-c schema:sameAs https://app.dimensions.ai/details/publication/pub.1045705046
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1016/0277-5379(86)90012-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026924483
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1016/0277-5379(89)90259-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007284388
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/s0140-6736(80)91066-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051618347
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1097/00000421-198910000-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003943693
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1111/j.1445-2197.1984.tb06679.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004642141
182 rdf:type schema:CreativeWork
183 https://www.grid.ac/institutes/grid.412920.c schema:alternateName Nottingham City Hospital
184 schema:name City Hospital, Nottingham, UK.
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...